- In November 2023, Boston Scientific concluded its acquisition of Relevant Medsystems, adding the Intracept Intraosseous Nerve Ablation System to its chronic pain portfolio. The acquisition, costing USD 850 million upfront plus contingent payments, expands access to vertebrogenic pain treatment through national coverage, benefiting over 150 million lives
- In April 2023, Abbott completed its acquisition of Cardiovascular Systems, Inc., a company known for its innovative atherectomy system used in treating vascular disease. CSI's system, which prepares vessels for angioplasty or stenting, became part of Abbott’s vascular portfolio. CSI shares ceased trading on Nasdaq that day
- In August 2022, Boston Scientific announced the acquisition of Obsidio, Inc., a company behind the GEM technology for embolization in peripheral vasculature. The semi-solid GEM material, recently FDA-cleared, simplifies embolization procedures with its unique gel-like properties. The transaction was not expected to affect Boston Scientific's 2022 earnings materially
- In February 2022, Medtronic received FDA approval for its Freezor and Freezor Xtra catheters to treat pediatric atrioventricular nodal reentrant tachycardia (AVRNT). This cryoablation therapy, is effective for over 140,000 patients worldwide, targets abnormal heart rhythms in children, helping to prevent life-threatening complications and support normal heart function
